Status:
UNKNOWN
Safety Study for Treatment of Wet Macular Degeneration Using the TheraSight(TM) Ocular Brachytherapy System
Lead Sponsor:
Theragenics Corporation
Conditions:
Macular Degeneration
Choroidal Neovascularization
Eligibility:
All Genders
50+ years
Phase:
PHASE1
PHASE2
Brief Summary
The study will investigate the safety and feasibility of using the TheraSight(TM) Brachytherapy System for treatment of wet age-related macular degeneration (AMD).
Detailed Description
This is a multi-center randomized study of three doses of radiation (assigned 1:1:1) delivered by the TheraSight(TM) Brachytherapy System in participants with choroidal neovascularization (CNV) second...
Eligibility Criteria
Inclusion
- Age 50 years or older.
- Active primary or recurrent subfoveal CNV secondary to AMD with minimally classic or occult lesion, where an active lesion is defined as one or more of the following:
- a) An increase \> 10% in lesion size (greatest linear dimension) on screening fluorescein angiography compared to previous fluorescein angiography no more than 180 days preceding screening visit
- b) Subretinal hemorrhage associated with CNV within 90 days of screening visit.
- c) Visual acuity loss \> 1 Snellen line in screening visual acuity compared to previous visual acuity no more than 180 days preceding screening
- Lesion \< 6 mm greatest linear dimension (GLD)
- Submacular blood must comprise less than 75% of the total lesion
- Subretinal fibrosis must comprise less than 25% of the total lesion
- Study eye best-corrected vision of 20/100 or poorer measured on an ETDRS chart (\< 48 letters correct)
- Fellow eye best-corrected vision that is at least one line better on an ETDRS chart than the best-corrected vision of the study eye
- HbA1c \< 6%
- Read and signed informed consent
Exclusion
- Prior AMD therapy treatment, including but not limited to laser and photodynamic therapy.
- Current or planned participation in the next 180 days in other experimental trials involving treatment of neovascular AMD in the study eye, ocular devices, or trials involving treatment for ocular conditions other than AMD.
- Prior ophthalmic surgery for the study eye other than cataract extraction and/or capsulotomy. A minimum interval of 180 days must elapse between cataract extraction or capsulotomy and study enrollment.
- Likely need for cataract surgery in study eye during the 180 days following TheraSight(TM) System treatment.
- Presence of other eye diseases that could compromise visual acuity in the study eye or that, in the clinical judgment of the evaluating study ophthalmologist, might create special risk for the study participant.
- CNV due to other causes such as ocular histoplasmosis or pathologic myopia.
- Endstage fibrotic disciform lesions.
- Diabetes requiring diet modification, or medication, or insulin.
- Current history of malignancy (except participants having basal cell carcinoma that was treated successfully, or other malignancy operated on or treated and in remission for five years prior to inclusion in the trial).
- Hypertensive retinopathy.
- Major cardiovascular or cerebrovascular event within the last year; examples include congestive heart failure, myocardial infarction, and stroke.
- Inability to complete follow-up.
- Allergy to fluorescein dye.
- Previous radiation to the study eye.
- Pregnancy at time of surgical procedure.
Key Trial Info
Start Date :
October 1 2004
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00100087
Start Date
October 1 2004
Last Update
June 24 2005
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
Theragenics Clinical Site
Atlanta, Georgia, United States
2
Theragenics Clinical Site
Augusta, Georgia, United States
3
Theragenics Clinical Site
Indianapolis, Indiana, United States
4
Theragenics Clinical Site
Boston, Massachusetts, United States